NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
nucana發佈癌症治療結果，看到1b/2期研究中的部分反應
NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid
nucana plc（納斯達克:NCNA）宣佈，正在進行的第1b/2模塊研究（NuTide:303）探究NUC-3373與PD-1抑制劑帕博利珠單抗聯合治療晚期固體腫瘤的初步數據
NuCana plc (NASDAQ:NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lung cancer (Module 2) have been published in MedRxiv, the preprint server for Health Sciences.
nucana plc（納斯達克:NCNA）宣佈，正在進行的第1b/2模塊研究（NuTide:303）探究NUC-3373與PD-1抑制劑帕博利珠單抗聯合治療晚期固體腫瘤（第1模塊），以及與紫杉醇聯合治療肺癌患者（第2模塊）的初步數據已經在健康科學的預印本服MedRxiv上發表
Module 1 included 12 patients with a variety of solid tumors who had exhausted all other treatment options. The majority...
第1模塊包括12名患有各種固體腫瘤且...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間